AFP and acute myeloid leukemia: Furthermore, the AFP patterns (timing, treatment duration, and agents) used at the study centers, their efficacy of prophylaxis for survival and prevention of bIFI, and the prescribers’ self-reported knowledge of AFP guidelines for patients with AML, MDS, and GvHD versus their clinical practice were investigated.